Skip to main content
Evidence Snapshot

Muscarinic acetylcholine receptor M4

CHEMBL1821 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:28:39Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1821
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Muscarinic acetylcholine receptor M4 as ChEMBL target CHEMBL1821, mapped to UniProt P08173. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Muscarinic acetylcholine receptor M4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1821
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P08173
Muscarinic acetylcholine receptor M4
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Muscarinic acetylcholine receptor M4 matters

As of 2026-09-13

Muscarinic acetylcholine receptor M4 is reviewed as Muscarinic acetylcholine receptor M4 (UniProt P08173); Muscarinic acetylcholine receptor M4 shows late clinical disease relevance led by schizophrenia.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 143 approved drugs, 4225 compounds, and 597 assays, with lead potency reaching pChEMBL 10.4.

Disease context
schizophrenia

Muscarinic acetylcholine receptor M4 shows late clinical disease relevance led by schizophrenia. 2 linked drugs keep the rationale reviewable. Linked drugs include XANOMELINE, XANOMELINE TARTRATE.

Start review with schizophrenia because it currently carries late clinical support. Linked drugs include XANOMELINE, XANOMELINE TARTRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 143 approved drugs, 4225 compounds, and 597 assays for this target. The dominant activity type is KI. CHEMBL3545181 is the current potency anchor at pChEMBL 10.4.

Use CHEMBL3545181 as the tractability anchor when discussing potency (pChEMBL 10.4).

Activity source · ChEMBL 36 via Core Engine
143 approved pChEMBL 10.4
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Muscarinic acetylcholine receptor M4 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P08173, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why schizophrenia is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

4225
Total Compounds
597
Total Assays
143
Approved Drugs
IC50: 1247.0, KI: 2407.0, EC50: 1058.0, KD: 8.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3545181
 10.4 IC50 Approved
No preferred name
CHEMBL5201074
 10.3 Kd —
No preferred name
CHEMBL4860528
 10.3 Kd —
No preferred name
CHEMBL5206565
 10.3 Kd —
No preferred name
CHEMBL5207281
 10.3 Kd —

Approved Drugs

Structure Compound First Approval
XANOMELINE
CHEMBL21536
 2024
PITOLISANT HYDROCHLORIDE
CHEMBL4164059
 2016
CARIPRAZINE HYDROCHLORIDE
CHEMBL2024517
 2015
ACLIDINIUM BROMIDE
CHEMBL551466
 2012
TIOTROPIUM BROMIDE
CHEMBL3545181
 2004
SOLIFENACIN
CHEMBL1734
 2004
DARIFENACIN
CHEMBL1346
 2004
TROSPIUM CHLORIDE
CHEMBL3084748
 2004
DESLORATADINE
CHEMBL1172
 2001
KETOTIFEN FUMARATE
CHEMBL1633
 1999
KETOTIFEN
CHEMBL534
 1999
TOLTERODINE
CHEMBL1382
 1998
QUETIAPINE
CHEMBL716
 1997
IRINOTECAN
CHEMBL481
 1996
OLANZAPINE
CHEMBL715
 1996
PAROXETINE
CHEMBL490
 1992
SERTRALINE
CHEMBL809
 1991
EBASTINE
CHEMBL305660
 1990
CLOZAPINE
CHEMBL42
 1989
CLOMIPRAMINE
CHEMBL415
 1989
ASTEMIZOLE
CHEMBL296419
 1988
MITOXANTRONE
CHEMBL58
 1987
OXYMETAZOLINE
CHEMBL762
 1986
SULCONAZOLE
CHEMBL1221
 1985
AMIODARONE
CHEMBL633
 1985
PENTAMIDINE
CHEMBL55
 1984
CYCLIZINE
CHEMBL648
 1982
GENTIAN VIOLET
CHEMBL64894
 1982
ECONAZOLE
CHEMBL808
 1982
DEXCHLORPHENIRAMINE
CHEMBL1201353
 1981
AMOXAPINE
CHEMBL1113
 1980
MAPROTILINE
CHEMBL21731
 1980
SULOCTIDIL
CHEMBL404849
 1979
SCOPOLAMINE
CHEMBL569713
 1979
TAMOXIFEN
CHEMBL83
 1977
CLEMASTINE
CHEMBL1626
 1977
OXYBUTYNIN
CHEMBL1231
 1975
MICONAZOLE
CHEMBL91
 1974
PERHEXILINE
CHEMBL75880
 1974
ACETYLCHOLINE
CHEMBL667
 1973
DIMENHYDRINATE
CHEMBL1200406
 1972
CARBACHOL
CHEMBL14
 1972
CARBAMOYLCHOLINE
CHEMBL965
 1972
DROPERIDOL
CHEMBL1108
 1970
DOXEPIN
CHEMBL1628227
 1969
DIPHENIDOL
CHEMBL936
 1967
DIPHENIDOL HYDROCHLORIDE
CHEMBL1529
 1967
NORTRIPTYLINE
CHEMBL445
 1964
THIORIDAZINE
CHEMBL479
 1962
CYPROHEPTADINE
CHEMBL516
 1961
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:28:39Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1821